市場調査レポート

院内感染:検査市場

Hospital Acquired Infections: Testing Markets

発行 Kalorama Information 商品コード 79624
出版日 ページ情報 英文 117 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
院内感染:検査市場 Hospital Acquired Infections: Testing Markets
出版日: 2012年08月14日 ページ情報: 英文 117 Pages
概要

当レポートでは、院内感染の検査市場について調査し、院内感染の市場規模推計と成長予測、市場に影響を及ぼす問題と動向、一般的な院内感染、院内感染の統計、国際的な入院期間の統計、分子試験vs.従来型の役割、主要サプライヤーの企業プロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション・産業動向

  • 概要
  • 病原体のイントロダクション
  • 抗菌生物の分類
  • 病院組織・感染リスク
  • 熱傷治療室
  • 集中治療室(ICU)
  • 救急診療部
  • 全身感染の統計
  • 入院期間
  • 感染リスクのある人口
  • 世界の人口統計
  • 平均余命
  • 経済動向
  • 医療費と実質健康転帰の比較
  • 感染・薬剤耐性
  • 薬剤耐性の原因
  • 選抜集団における薬剤耐性
  • 耐性を減らす方法
  • 入院患者のスクリーニング
  • 予防法
  • 感染減少に銅を使用する可能性
  • 広域消毒法
  • 感染検知・管理用ソフトウェア
  • 2009年米国再生・再投資法(The American Recovery and Reinvestment Act of 2009
  • )
  • 米国における州別の標準感染率
  • HAI(院内感染)承認・再承認の州レベルのケーススタディ
  • John T. Mather Memorial Hospital/Cepheid:ケーススタディ
  • メーカー・マーケッター動向
  • 提携・アライアンスの動向
  • ディベロッパーの動向

第3章 院内感染検査製品

  • 概要
  • 感染検査法
  • 薬剤耐性/感受性検査
  • 遺伝子型手法
  • 特定院内疾患検査
  • アシネトバクターバウマンニ
  • クロストリジウムディフィシレ
  • 院内(感染性)肺炎
  • 緑膿菌
  • 黄色ブドウ球菌
  • 結核
  • 尿路感染
  • バンコマイシン耐性腸球菌(VRE)
  • 人工呼吸器関連肺炎(VAP)
  • 新しい開発

第4章 院内感染検査の市場機会

  • 市場の懸念事項
  • 市場概要
  • 総市場規模・予測
  • 院内感染検査市場:地域別
  • 競合分析

第5章 企業プロファイル

  • イントロダクション
  • Abbott Laboratories
  • Alere
  • Becton, Dickinson
  • bioMerieux
  • Cephei
  • Gen-Probe
  • Meridian Bioscience, Inc.
  • Qiagen GmbH
  • Roche
  • Siemens AG

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI7091094

Abstract

A nosocomial, or hospital-acquired, infection is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections). The following are among the hospital infections considered in this report:

  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Hospital-Acquired Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Tuberculosis
  • Urinary Tract Infections
  • Vancomycin-resistant Enterococcus
  • Ventilator-Associated Pneumonia

This report focuses on testing for nosocomial infections. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the hospital setting, and b) the practical aspects of diagnosis and therapy are more meaningful based both on medial considerations and on market considerations. This report Hospital Acquired Infection Testing Markets looks at the market for diagnostics that address the growing nosocomial infection threat. As part of its coverage, the report includes the following information:

  • Market Size Estimate and Growth Forecast for the HAI Diagnostics Market
  • Issues and Trends Affecting Market
  • Common Hospital (nosocomial) Infections
  • Nosocomial Infection Statistics
  • International Hospital Length of Stay Statistics
  • The Role of Molecular Tests vs. Traditional
  • Corporate Profiles of Key Suppliers

Market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing and treatment needs.

The primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for diagnosing these infections. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.

Companies Profiled in the report include the following:

  • Abbott Laboratories
  • Alere
  • Becton, Dickinson
  • bioMerieux
  • Cephei
  • Gen-Probe
  • Meridian Bioscience, Inc.
  • Qiagen GmbH
  • Roche
  • Siemens AG

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Overview
  • Infection Control Summary
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Overview
  • Introduction to Pathogens
  • Classification of Antibacterial Organisms
  • Common Hospital (nosocomial) Infections
  • Hospital Units and Infection Risks
  • Burn Units
  • Intensive Care Units
  • Emergency Departments
  • General Infection Statistics
  • Nosocomial Infection Statistics
  • Hospital Length of Stay
  • Populations at Risk for Infection
  • Demographics of the World
  • Life Expectancy
  • Economic Trends
  • Comparison Between Healthcare Spending and Real Health Outcomes
  • Infections and Drug Resistance
  • Causes of Drug Resistance
  • Drug Resistance in Select Populations
  • Measures for Reducing Resistance
  • Screening Hospitalized patients
  • Prevention Measures
  • Potential Use of Copper for Reducing Infection
  • Wide Area Disinfection Methods
  • Software for Infection Detection and Control
  • The American Recovery and Reinvestment Act of 2009
  • U.S. Statewide Standardized Infection Ratio
  • State Level Case Study of HAI Admissions and Readmissions
  • John T. Mather Memorial Hospital/Cepheid-Case Study
  • Manufacturer and Marketer Trends
  • Trends in Partnerships and Alliances
  • Developers Trends

CHAPTER THREE: HOSPITAL INFECTION TESTING PRODUCTS

  • Overview
  • Methods of TransmissionTesting Methods
  • Drug-Resistance/Susceptibility Testing
  • Genotypic Methods
  • Specific Nosocomial Disease Testing
  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Hospital-Acquired Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Tuberculosis
  • Urinary Tract Infections
  • Vancomycin-resistant Enterococcus
  • Ventilator-Associated Pneumonia
  • New Developments

CHAPTER FOUR: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION TESTING

  • Market Considerations
  • Market Overview
  • Total Market Size and Forecast
  • Hospital Infection Testing Market by Geographical Region
  • Competitive Analysis

CHAPTER FIVE: COMPANY PROFILES

  • Introduction
  • Abbott Laboratories
  • Alere
  • Becton, Dickinson
  • bioMerieux
  • Cephei
  • Gen-Probe
  • Meridian Bioscience, Inc.
  • Qiagen GmbH
  • Roche
  • Siemens AG

APPENDIX: LIST OF MAJOR PROVIDERS

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Frequency of the Most Common Nosocomial Infections
  • Table 1-2: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
  • Figure 1-1: The World Market for Hospital Infection Testing/Diagnostics 2007-2016

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Table 2-1: Burn Statistics
  • Figure 2-1: U.S. Hospital Admissions and Percent of Hospital-acquired Infections (HAIs)
  • Table 2-2: U.S. Hospital Length of Stay, Average by Age Group
  • Table 2-3: Average International Length of Stay, by Country 2010
  • Table 2-4: World Population at Risk for Serious Bacterial Infections,Secondary to Chronic Diseases by Selected Geographical Region, 2010
  • Figure 2-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010
  • Table 2-5: Estimated World Population by Age and Geographical Region, 2010
  • Figure 2-3: Estimated World Population by Age and Geographical Region, 2010
  • Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2011
  • Figure 2-4: Average Life Expectancy in Years by Country 1980 and 2011
  • Table 2-7: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2010
  • Figure 2-5: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2010
  • Table 2-8: Healthcare Spending, Obesity and Life Expectancy, 2011
  • Table 2-9: U.S. States Hospital Acquired Infection Standardized Infection Ratio (SIR)
  • Table 2-10: Pennsylvania State Analysis of HAI Readmissions and Related Costs, 2009
  • Table 2-11: Pennsylvania State Analysis of HAIs, 2009

CHAPTER THREE: HOSPITAL INFECTION TESTING PRODUCTS

  • Table 3-1: Recent Approvals for Hospital Infection Testing
  • Table 3-2: New Developments, Hospital Infection Testing, as of July 2012

CHAPTER FOUR: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION TESTING

  • Table 4-1: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
  • Figure 4-1: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
  • Figure 4-2: The World Market for Hospital InfectionTesting/Diagnostics Estimated Market Share by Test Indication, 2011
  • Table 4-2: The World Market for Hospital Infection Testing/Diagnostics Estimated Products Sales by Geographic Region 2007-2016
  • Figure 4-3: The World Market for Hospital Infection Testing/Diagnostics Estimated Product Sales by Geographic Region 2007-2016
  • Figure 4-4: The World Market for Hospital Infection Testing/Diagnostics Estimated Market Share by Region, 2011
  • Table 4-3: The World Market for Hospital Infection Testing/Diagnostics Leading Suppliers' Shares Estimates for 2011
  • Figure 4-5: The World Market for Hospital Infection Testing/Diagnostics Leading Suppliers' Shares Estimates for 2011
Back to Top